Medtronic releases two-year results of SMART trial for TAVR
Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...
TCTMD9d
SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years
WASHINGTON, DC—Updated data from the SMART trial show that supra-annular self-expanding valves yield similar clinical outcomes as balloon-expandable valves at 2 years, but with less risk of ...
Nasdaq9d
Medtronic : Data Confirms Superior Valve Performance Of Evolut TAVR System In Small Annulus Patients
(RTTNews) - Medtronic plc (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, international head-to-head comparative trial of transfemoral ...
Zacks.com on MSN9d
Positive Trial Data on Evolut TAVR Likely to Support MDT Stock
At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.